Get the Stockscreener App
10.06
2.32%
-0.2286
Erasca Inc stock is traded at $10.06, with a volume of 2.33M.
It is down -2.32% in the last 24 hours and up +196.49% over the past month.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
See More
Previous Close:
$10.29
Open:
$10.29
24h Volume:
2.33M
Relative Volume:
0.59
Market Cap:
$2.86B
Revenue:
-
Net Income/Loss:
$-125.04M
P/E Ratio:
-12.27
EPS:
-0.82
Net Cash Flow:
$-122.99M
1W Performance:
+4.48%
1M Performance:
+196.49%
6M Performance:
+487.78%
1Y Performance:
+405.08%
1-Day Range:
$10.03
$10.48
1-Week Range:
$8.77
$10.67
52-Week Range:
$1.01
$10.67
Erasca Inc Stock (ERAS) Company Profile
Name
Erasca Inc
Sector
Industry
Phone
(858) 465-6511
Address
3115 MERRYFIELD ROW, SAN DIEGO
Compare ERAS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ERAS
Erasca Inc
|
10.06 | 2.92B | 0 | -125.04M | -122.99M | -0.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.63 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.34 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
811.57 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.84 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Erasca Inc Stock (ERAS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Initiated | Piper Sandler | Overweight |
| Oct-16-25 | Initiated | Stifel | Buy |
| Sep-03-25 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-18-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-26-25 | Initiated | Raymond James | Outperform |
| Nov-18-24 | Initiated | Jefferies | Buy |
| Mar-11-24 | Initiated | CapitalOne | Overweight |
| Jan-05-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-11-23 | Initiated | H.C. Wainwright | Buy |
| Mar-30-23 | Initiated | Mizuho | Buy |
| Feb-24-23 | Initiated | Goldman | Buy |
| Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Erasca Inc Stock (ERAS) Latest News
Erasca stock hits 52-week high at 10.46 USD By Investing.com - Investing.com Nigeria
Erasca Announces Major Underwritten Public Equity Offering - TipRanks
Erasca, Inc. Announces Upsized Public Offering of Common Stock - TradingView — Track All Markets
Erasca raises $225M to sharpen RAS oncology focus - BioWorld MedTech
Latham & Watkins Advises Erasca in Upsized US$225 Million Offering of Common Stock - Latham & Watkins LLP
Erasca prices $225M stock offering at $10 per share - MSN
A trio of biotechs targets $500M+ offerings - Endpoints News
Erasca stock hits 52-week high at 10.46 USD - Investing.com
Top 2 Tech Stocks That Are Ticking Portfolio Bombs - Benzinga
Erasca Announces Pricing of Upsized Public Offering of Common Stock - The Manila Times
Erasca, Inc. Announces Pricing of $225 Million Public Offering of Common Stock - Quiver Quantitative
Cancer drug developer Erasca raises $225M in stock sale - Stock Titan
Erasca Announces Pricing of Upsized Public Offering of Common Stock - GlobeNewswire Inc.
Top 2 Industrials Stocks That May Collapse In Q1 - Benzinga
Netflix, Erasca, Kraft Heinz And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Erasca plans to raise $150 million in public stock offering By Investing.com - Investing.com Nigeria
Erasca Announces $150 Million Public Offering; Stock Down - Nasdaq
Erasca Stock Pre-Market (-8.3%) : Announces $150M Public Stock Offering - Trefis
Erasca plans $150M public stock offering - MSN
Erasca stock falls after announcing $150 million public offering - Investing.com
Erasca announces proposed public offering of $150 million of common stock - marketscreener.com
Erasca (ERAS) Stock Slides After The Bell: Here's Why - Benzinga
Erasca (ERAS) Announces $150M Public Offering to Fund Cancer Research - Intellectia AI
Erasca reports preliminary year-end cash and securities of $341.8 million - Investing.com
Erasca, Inc. Announces Proposed Public Offering of $150 Million in Common Stock - Quiver Quantitative
Erasca Announces Proposed Public Offering of $150 Million of Common Stock - The Manila Times
Cancer drug developer Erasca plans $150M stock sale to fund R&D - Stock Titan
Erasca (ERAS) Soars 42% on Bullish Rating, PT Upgrade - Finviz
Erasca (ERAS) touches 3-year high as 4 analysts go bullish; gets 267% PT hike - MSN
Do Early ERAS-0015 Data Reframe Erasca’s (ERAS) Ambitions in RAS-Targeted Oncology? - simplywall.st
Erasca stock surges 42% in a week: Here's what you should know - MSN
Erasca (ERAS) Valuation Comes Into Focus After Early ERAS-0015 Data At JP Morgan Healthcare Conference - simplywall.st
Erasca Offers $7.50 Put Option, Attracting Investor Interest - Intellectia AI
Erasca (ERAS) Touches 3-Year High as 4 Analysts Go Bullish; Gets 267% PT Hike - Finviz
Erasca price target raised to $11 from $5 at Piper Sandler - TipRanks
Erasca Stock Surges 42% in a Week: Here's What You Should Know - Finviz
Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape - PR Newswire
HC Wainwright Has Strong Estimate for Erasca FY2027 Earnings - Defense World
Winners Losers: What is AXIS Capital Holdings Limiteds debt to equity ratioAnalyst Downgrade & Fast Gain Stock Tips - baoquankhu1.vn
Assessing Erasca (ERAS) Valuation After Encouraging Early ERAS-0015 Data At JP Morgan Conference - Yahoo Finance
Erasca Rallies Amid Acquisition Talks and Positive Price Target Revisions - StocksToTrade
Clear Street Elevates Erasca: Price Target Stands Tall at $11 - timothysykes.com
FY2027 Earnings Forecast for Erasca Issued By HC Wainwright - MarketBeat
Erasca (ERAS) Is Up 60.7% After Early ERAS-0015 Data Highlights Pan-RAS Franchise Ambitions - Yahoo Finance
Erasca (ERAS) Hits Fresh High Anew as Firm Gets up to 267% PT Hike - Insider Monkey
10 Stock With Eye-Popping Gains; 5 Are on Fresh Highs - Insider Monkey
Erasca stock hits 52-week high at 8.33 USD By Investing.com - Investing.com Nigeria
Erasca (NASDAQ:ERAS) Trading Up 7.7% Following Analyst Upgrade - Defense World
Erasca (ERAS) Price Target Increased by 30.91% to 6.53 - Nasdaq
Erasca stock jumps 10% as Wall Street lifts targets to $11 on ERAS-0015 data - TechStock²
Erasca stock hits 52-week high at 8.33 USD - Investing.com
Erasca Inc Stock (ERAS) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.38%
1.95%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):